POCI vs. INO, SPAI, HYPR, PDEX, NSPR, OBIO, FONR, ZJYL, EDAP, and NTRB
Should you be buying Precision Optics stock or one of its competitors? The main competitors of Precision Optics include Inovio Pharmaceuticals (INO), Safe Pro Group (SPAI), Hyperfine (HYPR), Pro-Dex (PDEX), InspireMD (NSPR), Orchestra BioMed (OBIO), Fonar (FONR), Jin Medical International (ZJYL), EDAP TMS (EDAP), and Nutriband (NTRB). These companies are all part of the "medical equipment" industry.
Precision Optics vs. Its Competitors
Precision Optics (NASDAQ:POCI) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.
In the previous week, Precision Optics had 5 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 8 mentions for Precision Optics and 3 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.76 beat Precision Optics' score of 0.02 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.
Inovio Pharmaceuticals has a net margin of 0.00% compared to Precision Optics' net margin of -30.28%. Precision Optics' return on equity of -51.33% beat Inovio Pharmaceuticals' return on equity.
Inovio Pharmaceuticals has a consensus target price of $8.80, indicating a potential upside of 262.14%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Precision Optics.
Precision Optics has higher revenue and earnings than Inovio Pharmaceuticals. Precision Optics is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Precision Optics has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.
13.7% of Precision Optics shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 16.3% of Precision Optics shares are held by insiders. Comparatively, 2.3% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Inovio Pharmaceuticals beats Precision Optics on 9 of the 16 factors compared between the two stocks.
Get Precision Optics News Delivered to You Automatically
Sign up to receive the latest news and ratings for POCI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding POCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precision Optics Competitors List
Related Companies and Tools
This page (NASDAQ:POCI) was last updated on 10/5/2025 by MarketBeat.com Staff
Free POCI Stock Alerts